Proton pump inhibitors: use and misuse in the clinical setting

References

• Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterol. 2004;134:1842–1860.
   Web of Science ®Google Scholar
• Sachs G, Shin G, Howden CW. The clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther. 2006;23(suppl):2–8.
   PubMed Web of Science ®Google Scholar
• Vigneri S, Tonini M, Scarpignato C, et al. Improving opportunities for effective management of gastro-oesophageal reflux disease. Dig Liver Dis. 2001;33:720–730.
   PubMedGoogle Scholar
• Savarino V, Mela GS, Zentilin P, et al. Comparison of 24-h control of gastric acidity by three different dosages of pantoprazole in patients with duodenal ulcer. Aliment Pharmacol Ther. 1998;12:1241–1247.
   PubMed Web of Science ®Google Scholar
• Malesci A, Savarino V, Zentilin P, et al. Partial regression of Barrett’s esophagus by long-term therapy with high-dose omeprazole. Gastrointest Endosc. 1996;44:700–705.
   PubMed Web of Science ®Google Scholar
• Katz MH. Failing the acid test: benefits of proton pump inhibitors may not justify the risks for many users. Arch Intern Med. 2010;170:747–748.
   PubMed Web of Science ®Google Scholar
• Cammarota S, Bruzzese D, Sarnelli G, et al. Proton pump inhibitors prescribing following the introduction of generic drugs. Eur J Clin Invest. 2012;42:1068–1078.
   PubMed Web of Science ®Google Scholar
• Inadomi JM, Fendrick AM. PPI use in the OTC era: who to treat, with what, and for how long? Clin Gastroenterol Hepatol. 2005;3:208–215.
   PubMed Web of Science ®Google Scholar
• Savarino V, Dulbecco P, De Bortoli N, et al. The appropriate use of proton pump inhibitors (PPIs): need for a reappraisal. Eur J Intern Med. 2017;45:160–168.
   Google Scholar
• Savarino V, Dulbecco P, Savarino E. Are proton pump inhibitors really so dangerous? Dig Liver Dis. 2016;48:851–859.
   PubMedGoogle Scholar
• Ladd AM, Panagopoulos G, Cohen J, et al. Potential costs of inappropriate use of proton pump inhibitors. Am J Med Sci. 2014;347::446–451.
   PubMed Web of Science ®Google Scholar
• Batuwitage BT, Kingham JG, Morgan NE, et al. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J. 2007;83::66–68.
   PubMed Web of Science ®Google Scholar
• Savarino E, Gemignani L, Pohl D, et al. Oesophageal motility and bolus transit abnormalities increase in parallel with the severity of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2011;34:476–486.
   PubMed Web of Science ®Google Scholar
• Frazzoni M, De Micheli E, Grisendi A, et al. Hiatal hernia is the key factor determining the lansoprazole dosage required for effective intra-oesophageal acid suppression. Aliment Pharmacol Ther. 2002;16:881–886.
   PubMed Web of Science ®Google Scholar
• Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterol. 1997;112:1798–1810.
   PubMed Web of Science ®Google Scholar
• Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitor in GORD: an overview of their pharmacology, efficacy and safety. Pharmacol Res. 2009;59:135–153.
   PubMed Web of Science ®Google Scholar
• Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. Int GORD Study Group Eur J Gastroenterol Hepatol. 1998;10:119–124.
   PubMed Web of Science ®Google Scholar
• Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med. 1995;333:1106–1110.
   PubMed Web of Science ®Google Scholar
• Labenz J, Armstrong D, Leodolter A, et al. Management of reflux esophagitis: does the choice of proton pump inhibitor matter? Int J Clin Pract. 2015;69:796–801.
   PubMed Web of Science ®Google Scholar
• Savarino E, Zentilin P, Savarino V. NERD: an umbrella term including heterogeneous subpopulations. Nat Rev Gastroenterol Hepatol. 2013;10:371–380.
   PubMed Web of Science ®Google Scholar
• Zentilin P, Dulbecco P, Savarino E, et al. Combined multichannel intraluminal impedance and pH-metry: a novel technique to improve detection of gastro-oesophageal reflux literature review. Dig Liver Dis. 2004;36:565–569.
   PubMedGoogle Scholar
• Savarino E, Bredenoord AJ, Fox M, et al. International working group for disorders of gastrointestinal motility and function. expert consensus document: advances in the physiological assessment and diagnosis of GERD. Nat Rev Gastroenterol Hepatol. 2017;14:665–676.
   PubMed Web of Science ®Google Scholar
• Roman S, Gyawali CP, Savarino E, et al. Ambulatory reflux monitoring for diagnosis of gastro-esophageal reflux disease: update of the Porto consensus and recommendations from an international consensus group. Neurogastroenterol Motil. 2017;29:1–15.
   PubMed Web of Science ®Google Scholar
• Gunaratnam NT, Jessup TP, Inadomi J, et al. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2006;23::1473–1477.
   PubMed Web of Science ®Google Scholar
• Savarino V, Mela GS, Zentilin P, et al. Antisecretory effects of three omeprazole regimens for maintenance treatment in duodenal ulcer. Dig Dis Sci. 1994;39:1473–1482.
   PubMed Web of Science ®Google Scholar
• Savarino V, Mela GS, Zentilin P, et al. Variability in individual response to various doses of omeprazole. Implications for antiulcer therapy. Dig Dis Sci. 1994;39:161–168.
   PubMed Web of Science ®Google Scholar
• van Pinxteren B, Numans ME, Bonis PA, et al. Shot-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-esophageal reflux disease-like symptoms and endoscopy-negative reflux disease. Cochrane Database Syst Rev. 2006;3:CD002095.
   Google Scholar
• Ates F, Vaezi MF. Approach to the patient with presumed extra-esophageal GERD. Best Pract Res Clin Gastroenterol. 2013;27:415–431.
   PubMed Web of Science ®Google Scholar
• Kahrilas PJ, Howden CW, Hughes N, et al. Response of chronic cough to acid-suppressive therapy in patients with gastroesophageal reflux disease. Chest. 2013;143:605–612.
   PubMed Web of Science ®Google Scholar
• Gatta L, Vaira D, Sorrenti G, et al. Meta-analysis: the efficacy of proton pump inhibitors for laryngeal symptoms attributed to gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2007;25:385–392.
   PubMed Web of Science ®Google Scholar
• Scarpignato C. Pharmacological bases of the medical treatment of gastroesophageal reflux disease. Dig Dis. 1988;6:117–148.
   PubMed Web of Science ®Google Scholar
• Gibson PG, Henry RL, Coughlan JL. Gastro-oesophageal reflux treatment for asthma in adults and children. Cochrane Database Syst Rev. 2003;2:CD001496.
   PubMed Web of Science ®Google Scholar
• Kiljander TO, Harding SM, Field SK, et al. Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial. Am J Respir Crit Care Med. 2006;173:1091–1097.
   PubMed Web of Science ®Google Scholar
• de Bortoli N, Nacci A, Savarino E, et al. How many cases of laryngopharyngeal reflux suspected by laryngoscopy are gastroesophageal reflux disease-related? World J Gastroenterol. 2012;18:4363–4370.
   PubMed Web of Science ®Google Scholar
• Scarpignato C, Gatta L, Zullo A, et al. SIF-AIGO-FIMMG group; Italian society of pharmacology, the Italian association of hospital gastroenterologists, and the Italian federation of general practitioners. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Medicine. 2016;14::179–214.
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Aguirre TV, Davis S, et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett’s esophagus. Am J Gastroenterol. 2004;99:1877–1883.
   PubMed Web of Science ®Google Scholar
• Hillman LC, Chiragakis L, Shadbolt B, et al. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett’s oesophagus. Med J Aust. 2004;180:387–391.
   PubMed Web of Science ®Google Scholar
• Kastelein F, Spaander MC, Steyerberg EW, et al. ProBar study group. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett’s esophagus. Clin Gastroenterol Hepatol. 2013;11:382–388.
   PubMed Web of Science ®Google Scholar
• Jankowski JAZ, de Caestecker J, Love SB, et al. Esomeprazole and aspirin in Barrett’s oesophagus (AspECT): a randomised factorial trial. Lancet. 2018;392:400–408.
   PubMed Web of Science ®Google Scholar
• Roman S, Savarino E, Savarino V, et al. Eosinophilic oesophagitis: from physiopathology to treatment. Dig Liver Dis. 2013;45:871–878.
   PubMedGoogle Scholar
• Gyawali CP, Roman S, Bredenoord AJ, et al. International GERD consensus working group. Classification of esophageal motor findings in gastro-esophageal reflux disease: conclusions from an international consensus group. Neurogastroenterol Motil. 2017;29. DOI:10.1111/nmo.13104.
   Web of Science ®Google Scholar
• Molina-Infante J, Bredenoord AJ, Cheng E, et al. PPI-REE task force of the European Society of Eosinophilic Oesophagitis (EUREOS). Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis. Gut. 2016;65:524–531.
   PubMed Web of Science ®Google Scholar
• Savarino EV, Tolone S, Bartolo O, et al. The GerdQ questionnaire and high resolution manometry support the hypothesis that proton pump inhibitor-responsive oesophageal eosinophilia is a GERD-related phenomenon. Aliment Pharmacol Ther. 2016;44:522–530.
   PubMed Web of Science ®Google Scholar
• Kedika RR, Souza RF, Spechler SJ. Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci. 2009;54:2312–2317.
   PubMed Web of Science ®Google Scholar
• de Bortoli N, Penagini R, Savarino E, et al. Eosinophilic esophagitis: update in diagnosis and management. Position paper by the Italian Society of Gastroenterology and Gastrointestinal Endoscopy (SIGE). Dig Liver Dis. 2017;49:254–260.
   PubMedGoogle Scholar
• Zagari RM, Romano M, Ojetti V, et al. Guidelines for the management of Helicobacter pylori infection in Italy: the III working group consensus report 2015. Dig Liver Dis. 2015;47:903–912.
   PubMedGoogle Scholar
• Graham DY, Lew GM, Klein PD, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med. 1992;116:705–708.
   PubMed Web of Science ®Google Scholar
• Nyssen OP, McNicholl AG, Megraud F, et al. Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2016;CD009034.
   PubMed Web of Science ®Google Scholar
• Ford A, Delaney B, Forman D, et al. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev. 2004;CD003840.
   PubMed Web of Science ®Google Scholar
• Fallone CA, Chiba N, van Zanten SV, et al. The toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterol. 2016;151(51–69):e14.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Calvet X. Review article: Helicobacter pylori-negative duodenal ulcer disease. Aliment Pharmacol Ther. 2009;30:791–815.
   PubMed Web of Science ®Google Scholar
• Freston JW. Review article: role of proton pump inhibitors in non-H. Aliment Pharmacol Ther. 2001;15(Suppl 2):2–5.
   PubMed Web of Science ®Google Scholar
• Bytzer P, Teglbjaerg PS. Danish ulcer study group. Helicobacter pylori-negative duodenal ulcers: prevalence, clinical characteristics, and prognosis--results from a randomized trial with 2-year follow-up. Am J Gastroenterol. 2001;96:1409–1416.
   PubMed Web of Science ®Google Scholar
• Harris AW, Gummett PA, Phull PS, et al. Recurrence of duodenal ulcer after Helicobacter pylori eradication is related to high acid output. Aliment Pharmacol Ther. 1997;11:331–334.
   PubMed Web of Science ®Google Scholar
• Howden CW, Leontiadis GI. Current indications for acid suppressants in Helicobacter pylori -negative ulcer disease. Best Pract Res Clin Gastroenterol. 2001;15:401–412.
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Delaney BC, Vakil N, et al. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterol. 2004;127:1329–1337.
   PubMed Web of Science ®Google Scholar
• Savarino V, Mela GS, Zentilin P, et al. Effect of one-month treatment with nonsteroidal antiinflammatory drugs (NSAIDs) on gastric pH of rheumatoid arthritis patients. Dig Dis Sci. 1998;43:459–463.
   PubMed Web of Science ®Google Scholar
• Salas M, Ward A, Caro J. Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials. BMC Gastroenterol. 2002;2:17.
   PubMedGoogle Scholar
• Malfertheiner P, Megraud F, O’Morain CA, et al. European Helicobacter and microbiota study group and consensus panel. Management of Helicobacter pylori infection-the maastricht V/florence consensus report. Gut. 2017;66:6–30.
   PubMed Web of Science ®Google Scholar
• Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev. 2006;CD002094.
   PubMed Web of Science ®Google Scholar
• Zhang YS, Li Q, He BS, et al. Proton pump inhibitors therapy vs H2 receptor antagonists therapy for upper gastrointestinal bleeding after endoscopy: A meta-analysis. World J Gastroenterol. 2015;21:6341–6351.
   PubMed Web of Science ®Google Scholar
• Berstad A. Does profound acid inhibition improve haemostasis in peptic ulcer bleeding? Scand J Gastroenterol. 1997;32:396–398.
   PubMed Web of Science ®Google Scholar
• Patchett SE, Enright H, Afdhal N, et al. Clot lysis by gastric juice: an in vitro study. Gut. 1989;30:1704–1707.
   PubMed Web of Science ®Google Scholar
• Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol. 2012;107:345–360.
   PubMed Web of Science ®Google Scholar
• Sachar H, Vaidya K, Laine L. Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis. JAMA Intern Med. 2014;174:1755–1762.
   PubMed Web of Science ®Google Scholar
• Sung JJ, Barkun A, Kuipers EJ, et al. Peptic ulcer bleed study group. Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial. Ann Intern Med. 2009;150:455–464.
   PubMed Web of Science ®Google Scholar
• Moore RA, Derry S, Phillips CJ, et al. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. BMC Musculoskelet Disord. 2006;7:79.
   PubMed Web of Science ®Google Scholar
• Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002;CD002296.
   PubMedGoogle Scholar
• Tran-Duy A, Vanmolkot FH, Joore MA, et al. Should patients prescribed long-term low-dose aspirin receive proton pump inhibitors? A systematic review and meta-analysis. Int J Clin Pract. 2015;69:1088–1111.
   PubMed Web of Science ®Google Scholar
• Jensen RT, Niederle B, Mitry E, et al. Frascati consensus conference; european neuroendocrine tumor society. gastrinoma (duodenal and pancreatic). Neuroendocrinol. 2006;84:173–182.
   PubMed Web of Science ®Google Scholar
• Jensen RT, Cadiot G, Brandi ML, et al. Barcelona consensus conference participants. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinol. 2012;95:98–119.
   PubMed Web of Science ®Google Scholar
• Wilcox CM, Hirschowitz BI. Treatment strategies for Zollinger-Ellison syndrome. Expert Opin Pharmacother. 2009;10:1145–1157.
   PubMed Web of Science ®Google Scholar
• Bardou M, Quenot JP, Barkun A. Stress-related mucosal disease in the critically ill patient. Nat Rev Gastroenterol Hepatol. 2015;12:98–107.
   PubMed Web of Science ®Google Scholar
• Alhazzani W, Alenezi F, Jaeschke RZ, et al. Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Crit Care Med. 2013;41:693–705.
   PubMed Web of Science ®Google Scholar
• Barkun AN, Bardou M, Pham CQ, et al. Proton pump inhibitors vs. histamine 2 receptor antagonists for stress-related mucosal bleeding prophylaxis in critically ill patients: a meta-analysis. Am J Gastroenterol. 2012;107:507–520.
   PubMed Web of Science ®Google Scholar
• Stanghellini V, Chan FK, Hasler WL, et al. Gastroduodenal disorders. Gastroenterol. 2016;150:1380–1392.
   PubMed Web of Science ®Google Scholar
• Savarino V, Mela GS, Zentilin P, et al. Circadian gastric acidity in Helicobacter pylori positive ulcer patients with and without gastric metaplasia in the duodenum. Gut. 1996;39:508–512.
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Soo S, Deeks J, et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006;CD001960.
   PubMed Web of Science ®Google Scholar
• Wang WH, Huang JQ, Zheng GF, et al. Effects of proton-pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials. Clin Gastroenterol Hepatol. 2007;5:178–185.
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence. Management of dyspepsia in adults in primary care. [ updated 2004 Aug; cited 2005 Jul].
   Google Scholar
• van Vliet EP, Otten HJ, Rudolphus A, et al. Inappropriate prescription of proton pump inhibitors on two pulmonary medicine wards. Eur J Gastroenterol Hepatol. 2008;20:608–612.
   PubMed Web of Science ®Google Scholar
• Reid M, Keniston A, Heller JC, et al. Inapprpriate prescribing of proron pump inhibitors in hospitalized patients. J Hosp Med. 2012;7:421–425.
   PubMed Web of Science ®Google Scholar
• Thomas L1, Culley EJ, Gladowski P, et al. Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization. J Manag Care Pharm. 2010;16:122–129.
   PubMed Web of Science ®Google Scholar
• Gupta R, Garg P, Kottoor R, et al. Oversuse of acid suppression therapy in hospitalized patients. South Med J. 2010;103:207–211.
   PubMed Web of Science ®Google Scholar
• Heidelbaugh JJ, Inadomi JM. Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients. Am J Gastroenterol. 2006;101:2200–2205.
   PubMed Web of Science ®Google Scholar
• Zink DA, Pohlman M, Barnes M, et al. Long-term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther. 2005;21:1203–1209.
   PubMed Web of Science ®Google Scholar
• Heidelbaugh JJ, Kim AH, Chang R, et al. Overutilization of proton-pump inhibitors: what the clinician needs to know. Therap Adv Gastroenterol. 2012;5:219–232.
   PubMed Web of Science ®Google Scholar
• Ahrens D, Behrens G, Himmel W, et al. Appropriateness of proton pump inhibitor recommendations at hospital discharge and continuation in primary care. Int J Clin Pract. 2012;66:767–773.
   PubMed Web of Science ®Google Scholar
• Savarino E, Pohl D, Zentilin P, et al. Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. Gut. 2009;58:1185–1191.
   PubMed Web of Science ®Google Scholar
• de Bortoli N, Frazzoni L, Savarino EV, et al. Functional Heartburn overlaps with irritable bowel syndrome more often than GERD. Am J Gastroenterol. 2016;111:1711–1717.
   PubMed Web of Science ®Google Scholar
• Zerbib F, Belhocine K, Simon M, et al. Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease. Gut. 2012;61:501–506.
   PubMed Web of Science ®Google Scholar
• Hernández-Díaz S, Rodríguez LA. Steroids and risk of upper gastrointestinal complications. Am J Epidemiol. 2001;153:1089–1093.
   PubMed Web of Science ®Google Scholar
• Luo JC, Chang FY, Lin HY, et al. The potential risk factors leading to peptic ulcer formation in autoimmune disease patients receiving corticosteroid treatment. Aliment Pharmacol Ther. 2002;16:1241–1248.
   PubMed Web of Science ®Google Scholar
• Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med. 1994;236:619–632.
   PubMed Web of Science ®Google Scholar
• Dorlo TP, Jager NG, Beijnen JH, et al. [Concomitant use of proton pump inhibitors and systemic corticosteroids]. Ned Tijdschr Geneeskd. 2013;157:A5540.
   PubMedGoogle Scholar
• Laine L, Bombardier C, Hawkey CJ, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterol. 2002;123:1006–1012.
   PubMed Web of Science ®Google Scholar
• de Abajo FJ. Effects of selective serotonin reuptake inhibitors on platelet function: mechanisms, clinical outcomes and implications for use in elderly patients. Drugs Aging. 2011;28:345–367.
   PubMed Web of Science ®Google Scholar
• Ray WA1, Chung CP2, Murray KT3, et al. Association of proton pump inhibitors with reduced risk of warfarin-related serious upper gastrointestinal bleeding. Gastroenterol. 2016;151:1105–1112.
   PubMed Web of Science ®Google Scholar
• Teichert M, van Noord C, Uitterlinden AG, et al. Proton pump inhibitors and the risk of overcoagulation during acenocoumarol maintenance treatment. Br J Hematol. 2011;153:379–385.
   PubMed Web of Science ®Google Scholar
• Lin KJ1, Hernández-Díaz S, García Rodríguez LA. Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy. Gastroenterol. 2011;141:71–79.
   PubMed Web of Science ®Google Scholar
• Agewall S, Cattaneo M, Collet JP, et al. ESC working group on cardiovascular pharmacology and drug therapy and ESC working group on thrombosis. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J. 2013;34:1708–1713, 1713a–1713b.
   Web of Science ®Google Scholar
• Chen M, Wei JF, Xu YN, et al. A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel. Cardiovasc Ther. 2012;30:e227–233.
   PubMed Web of Science ®Google Scholar
• Savarino V, Mela GS, Zentilin P, et al. Evaluation of 24-hour gastric acidity in patients with hepatic cirrhosis. J Hepatol. 1996;25:152–157.
   PubMed Web of Science ®Google Scholar
• Deshpande A, Pasupuleti V, Thota P, et al. Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. J Gastroenterol Hepatol. 2013;28:235–242.
   PubMed Web of Science ®Google Scholar
• van Boxel OS, Hagenaars MP, Smout AJ, et al. Socio-demographic factors influence chronic proton pump inhibitor use by a large population in the Netherlands. Aliment Pharmacol Ther. 2009;29:571–579.
   PubMed Web of Science ®Google Scholar
• Haastrup PF, Paulsen MS, Christensen RD, et al. Medical and non-medical predictors of initiating long-term use of proton pump inhibitors: a nationwide cohort study of first-time users during a 10-year period. Aliment Pharmacol Ther. 2016;44:78–87.
   PubMed Web of Science ®Google Scholar
• Targownik LE, Metge C, Roos L, et al. The prevalence of and the clinical and demographic characteristics associated with high-intensity proton pump inhibitor use. Am J Gastroenterol. 2007;102:942–950.
   PubMed Web of Science ®Google Scholar
• Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336(7634):2–3.
   PubMed Web of Science ®Google Scholar
• Eusebi LH, Rabitti S, Artesiani ML, et al. Proton pump inhibitors: risks of long-term use. J Gastroenterol Hepatol. 2017;32:1295–1302.
   PubMed Web of Science ®Google Scholar
• Reimer C, Søndergaard B, Hilsted L, et al. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterol. 2009;137:80–87.
   PubMed Web of Science ®Google Scholar
• Niklasson A, Lindström L, Simrén M, et al. Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Am J Gastroenterol. 2010;105:1531–1537.
   PubMed Web of Science ®Google Scholar
• Reimer C, Bytzer P. Discontinuation of long-term proton pump inhibitor therapy in primary care patients: a randomized placebo-controlled trial in patients with symptom relapse. Eur J Gastroenterol Hepatol. 2010;22:1182–1188.
   PubMed Web of Science ®Google Scholar
• Targownik L. Discontinuing long-term PPI therapy: why, with whom, and how? Am J Gastroenterol. 2018;113:519–528.
   PubMed Web of Science ®Google Scholar